Relmada Therapeutics (RLMD) Corporate presentation summary

Investment highlights and pipeline

• NDV-01, a sustained-release Gem/Doce therapy, leads a pipeline targeting non-muscle invasive bladder cancer (NMIBC) with a well-defined regulatory path and strong commercial potential.

• NDV-01 offers improved administration, extended tumor exposure, and leverages physician familiarity, aiming to become a next-generation standard of care.

• The pipeline includes late-stage and exploratory studies in NMIBC and a novel candidate, sepranolone, for compulsivity disorders.

• Leadership team has deep expertise in urology and NMIBC clinical practice.

NMIBC market and treatment landscape

• NMIBC accounts for 80% of new bladder cancer cases, representing a multi-billion dollar market with high recurrence rates and complex treatment pathways.

• Recurrence rates are high, with up to 61% of high-risk patients recurring within one year and significant procedural and mental health burdens.

• Current treatments include TURBT, intravesical chemotherapy, and immunotherapies, but have limitations such as high recurrence, supply issues, and complex handling.

NDV-01 product profile and advantages

• NDV-01 is a ready-to-use, office-based therapy administered in under 5 minutes, enabling broader community adoption.

• Provides sustained intravesical drug release for up to 10 days, improving tumor exposure and potentially reducing dosing frequency.

• Biodegradable polymer ensures safe excretion, differentiating it from competitors requiring device extraction.

• Demonstrates stable, predictable drug levels in vitro, minimizing systemic side effects.